Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
- Registration Number
- NCT02172495
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4700
Inclusion Criteria
- Men and women aged at least 40 years with the symptoms of Chronic Obstructive Pulmonary Disease
Read More
Exclusion Criteria
- Patients with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Symptoms of COPD Tiotropium bromide Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
- Primary Outcome Measures
Name Time Method Occurrence of Adverse Events 4 weeks Change from baseline in breathlessness when walking/climbing stairs Baseline, after 4 weeks Change from baseline in overall severity of the clinical picture Baseline, after 4 weeks Change from baseline in breathlessness during everyday activities Baseline, after 4 weeks Change from baseline in breathlessness on physical exercise Baseline, after 4 weeks Change from baseline in breathlessness during housework Baseline, after 4 weeks
- Secondary Outcome Measures
Name Time Method